A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Prajapati, S. T.
- Recent Advances in Transdermal Drug Delivery System
Authors
1 Department of Pharmaceutics and Pharmaceutical Technology, Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana-384 001, IN
Source
Research Journal of Pharmaceutical Dosage Form and Technology, Vol 2, No 2 (2010), Pagination: 113-119Abstract
Human skin serves a protective function by imposing physicochemical limitations. For a drug to be delivered passively via the skin it needs to have a suitable lipophilicity and a molecular weight < 500 Da. The number of commercially available products based on transdermal or dermal delivery has been limited by these requirements. In recent years various passive and active strategies have emerged to optimize delivery. The passive approach entails the optimization of formulation or drug carrying vehicle to increase skin permeability. However, passive methods do not greatly improve the permeation of drugs with molecular weights >500 Da. In contrast, active methods, normally involving physical or mechanical methods of enhancing delivery, have been shown to be generally superior. The delivery of drugs of differing lipophilicity and molecular weight, including proteins, peptides and oligonucletides, has been shown to be improved by active methods such as iontophoresis, electroporation, mechanical perturbation and other energy-related techniques such as ultrasound and needleless injection.Keywords
Techniques For Transdermal Delivery, Microneedle, Radiofrequency Drug Delivery System, Iontophoresis.
- Design and Evaluation of Modified Release Dosage Form Containing Bupropion Hydrochloride
Authors
1 Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana-384 001, IN
2 Parul Institute of Pharmacy, Baroda-391760, IN
3 Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana-384 001, IN
Source
Research Journal of Pharmaceutical Dosage Form and Technology, Vol 2, No 1 (2010), Pagination: 47-51Abstract
In the present investigation an attempt was made to reduce the frequency of dose administration, to improve the patient compliance by developing Modified release matrix tablet of Bupropion Hydrochloride (BPH). Bupropion has been approved by the Food and Drug Administration (FDA) for use in smoking cessation. Eleven batches of matrix tablets of BPH were developed by using direct compression technique and coated with Opadry white. Compressed tablets were evaluated for weight variation, hardness, friability, similarity factor (f2) and in vitro dissolution using paddle (USP type II) method. Drug excipients compatibility study was also performed using differential scanning calorimetry (DSC). All the formulations were compared with the innovator. Among the eleven formulations F11 batch shows comparative dissolution profile with the innovator.